Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$1.79 - $2.9 $2.48 Million - $4.03 Million
-1,387,943 Reduced 62.72%
825,009 $2.03 Million
Q2 2022

Aug 15, 2022

SELL
$4.41 - $5.69 $3.18 Million - $4.1 Million
-720,000 Reduced 24.55%
2,212,952 $11.7 Million
Q3 2021

Nov 12, 2021

BUY
$4.79 - $6.68 $1.45 Million - $2.02 Million
302,985 Added 11.52%
2,932,952 $17.9 Million
Q2 2021

Aug 13, 2021

BUY
$5.35 - $6.35 $3.21 Million - $3.81 Million
600,000 Added 29.56%
2,629,967 $15.5 Million
Q4 2020

Feb 12, 2021

BUY
$5.25 - $8.56 $2.63 Million - $4.28 Million
500,000 Added 32.68%
2,029,967 $14 Million
Q4 2019

Feb 18, 2020

SELL
$3.84 - $4.86 $326,526 - $413,260
-85,033 Reduced 5.27%
1,529,967 $6.46 Million
Q3 2019

Nov 14, 2019

SELL
$4.86 - $6.05 $1.04 Million - $1.3 Million
-215,000 Reduced 11.75%
1,615,000 $8.33 Million
Q2 2019

Aug 15, 2019

BUY
$4.51 - $6.6 $859,565 - $1.26 Million
190,591 Added 11.63%
1,830,000 $10.3 Million
Q1 2019

May 15, 2019

BUY
$5.16 - $6.85 $1.65 Million - $2.19 Million
319,409 Added 24.2%
1,639,409 $10.2 Million
Q4 2018

Feb 14, 2019

BUY
$4.89 - $7.16 $1.44 Million - $2.11 Million
294,000 Added 28.65%
1,320,000 $6.69 Million
Q3 2018

Nov 14, 2018

BUY
$6.89 - $7.78 $1.55 Million - $1.75 Million
225,000 Added 28.09%
1,026,000 $7.4 Million
Q2 2018

Aug 14, 2018

SELL
$5.19 - $7.25 $726,600 - $1.02 Million
-140,000 Reduced 14.88%
801,000 $5.34 Million
Q1 2018

May 09, 2018

SELL
$3.56 - $5.74 $462,800 - $746,200
-130,000 Reduced 12.14%
941,000 $5.16 Million
Q4 2017

Feb 14, 2018

BUY
$2.76 - $3.95 $1.41 Million - $2.01 Million
510,100 Added 90.94%
1,071,000 $3.62 Million
Q3 2017

Nov 15, 2017

BUY
$2.22 - $2.73 $1.25 Million - $1.53 Million
560,900
560,900 $1.53 Million

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $308M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Bamco Inc Portfolio

Follow Bamco Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bamco Inc , based on Form 13F filings with the SEC.

News

Stay updated on Bamco Inc with notifications on news.